project cancelled

Corticotherapy is widely used in auto-immune diseases. If induced immunosuppression by corticosteroids is well admitted, it's currently not possible to determine individual risk of infection. Thus, the development of new biomarkers able to reflect immunological status under immunosuppressive treatments is needed. It would help identifying patients who would benefit from adapted treatment protocols or infectious prophylaxis. In this field, the mHLA-DR (monocyte Human Leukocyte Antigen-DR) has shown encouraging results. However, it has never been used in patients treated by immunosuppressive therapies. The investigators aim to describe changes induced by corticosteroids in mHLA-DR expression in vivo. To achieve this goal, the investigators will measure mHLA-DR before treatment, after 1 months, 3 months and 6 months of treatment. Finally, the investigators will look for correlation between the level of expression of mHLA-DR and the cumulated dose of corticosteroids administered.

Inclusion Criteria:

• Patient aged of 18 years old or more, male or female.
• Patient diagnosed with any pathology indicating a treatment by corticotherapy at 1mg/kg/day.
• Patient who didn't express any opposition to be enrolled in the study after reading the dedicated information letter.
• Patient affiliated to social heath care regimen

Exclusion Criteria:

• Treatment by corticosteroids in the previous 6 months.

  • Immunsuppressive treatment (except for corticosteroids) in the previous 2 years.
  • Patient under judicial protection, guardianship or curators

Patient Diagnosed With Any Pathology Indicating a Treatment by Corticotherapy